NCT00337376View on ClinicalTrials.gov

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

PHASE1TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Advanced Solid Cancers
Interventions
DRUG

Rapamune

Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO

DRUG

Abraxane

intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.

Trial Locations (1)

06520

Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Yale University

OTHER

NCT00337376 - A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers | Biotech Hunter | Biotech Hunter